Short summary

This study will investigate the use of drugs for treatment of OAB among people in Danish nursing homes. A few nursing homes will be invited to participate in the study. The data collection will include the drug(s) used to treat OAB and information about their use of pads and facilities. The data will be collected from residents treated for OAB with help from the nursing home staff. In addition, we will conduct individual interviews with selected residents to explore their perception of treatment

Rationale

OAB is a chronic medical condition and has a serious impact on the quality of life (QOL) in both men and women. There is a high incidence of OAB among older people which affects daily activities and social function. In 2020, 46,000 Danes were registered with OAB of which the older people (≥65 years) accounted for 70% of the cases. Today OAB is treated with beta-3-agonists or antimuscarinic drugs as the most frequent. In 2020, the economic burden for OAB treatment at a national level was 56,000,000 DDK.

There is poor evidence for the effect of the treatment, especially among older people, and, in addition, the treatment is associated with several serious side effects such as cardiac arrhythmias, cognitive influence, and increased tendency to fall.

The aim of this study is to investigate the use of drugs for treatment of OAB in elderly at Danish nursing homes, including the effect and potential side effects of treatment.

Description of the cohort

Nursing home residents recruited from all five regions of Denmark.

Data and biological material

Gender, age, nursing home, type of drug, amount, dosing interval, duration of treatment, catheter, use of pad, use of wheelchair or walker.

Interview responses from some nursing homes residents

Collaborating researchers and departments

Reagens

• Owner, Pharmacist, Søren Post

Hospital Pharmacy Funen

• Professor, Head of Research, Anton Pottegård
• Postdoc, Pharmacist, Carina Lundby
• Pharmacist Cathrine Simone Kahya